AIM ImmunoTech Inc. financial data

Symbol
AIM on NYSE
Industry
Biological Products, (No Diagnostic Substances)
Location
2117 Sw Highway 484, Ocala, FL
State of incorporation
DE
Fiscal year end
December 31
Former names
HEMISPHERX BIOPHARMA INC (to 8/26/2019)
Latest financial report
10-K - Q4 2024 - Mar 27, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 87.1 % -84.1%
Debt-to-equity 332 %
Return On Equity -553 % -368%
Return On Assets -128 % -30.8%
Operating Margin -11.6K % +26.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 72.3M shares +44.9%
Common Stock, Shares, Outstanding 65.5M shares +33.4%
Entity Public Float 20.8M USD -34.7%
Common Stock, Value, Issued 66K USD +34.7%
Weighted Average Number of Shares Outstanding, Basic 56M shares +15.3%
Weighted Average Number of Shares Outstanding, Diluted 56M shares +15.3%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 170K USD -15.8%
Revenue from Contract with Customer, Excluding Assessed Tax 170K USD -15.8%
Research and Development Expense 6.2M USD -43.3%
General and Administrative Expense 13.7M USD -35.1%
Costs and Expenses 19.9M USD -37.9%
Operating Income (Loss) -19.8M USD +38.1%
Net Income (Loss) Attributable to Parent -17.3M USD +40.2%
Earnings Per Share, Basic -0.31 USD/shares +48.3%
Earnings Per Share, Diluted -0.31 USD/shares +48.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1.7M USD -68.7%
Marketable Securities, Current 2.28M USD -70.2%
Accounts Receivable, after Allowance for Credit Loss, Current 1.18M USD -29.4%
Assets, Current 4.18M USD -71.3%
Property, Plant and Equipment, Net 108K USD -15%
Operating Lease, Right-of-Use Asset 618K USD -11.3%
Other Assets, Noncurrent 1.11M USD -34.1%
Assets 8.61M USD -55.6%
Accounts Payable, Current 6.38M USD -0.93%
Employee-related Liabilities, Current 1K USD -99.8%
Accrued Liabilities, Current 606K USD -69.5%
Liabilities, Current 9.54M USD +10.2%
Operating Lease, Liability, Noncurrent 395K USD -20.2%
Liabilities 9.93M USD +8.56%
Retained Earnings (Accumulated Deficit) -427M USD -4.23%
Stockholders' Equity Attributable to Parent -1.32M USD -113%
Liabilities and Equity 8.61M USD -55.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.82M USD -30.8%
Net Cash Provided by (Used in) Financing Activities 2.83M USD +2729%
Net Cash Provided by (Used in) Investing Activities -158K USD -103%
Common Stock, Shares Authorized 350M shares 0%
Common Stock, Shares, Issued 65.5M shares +33.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2.14M USD +41.4%
Deferred Tax Assets, Valuation Allowance 42.9M USD +16.5%
Deferred Tax Assets, Gross 42.9M USD +11.6%
Operating Lease, Liability 634K USD -11.7%
Depreciation 9K USD -18.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -17.3M USD +40.2%
Property, Plant and Equipment, Gross 1.47M USD -5.72%
Operating Lease, Liability, Current 239K USD +7.18%
Lessee, Operating Lease, Liability, to be Paid, Year Two 254K USD +10.9%
Lessee, Operating Lease, Liability, to be Paid, Year One 293K USD +5.02%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 72K USD -41.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 159K USD -20.5%
Deferred Tax Assets, Operating Loss Carryforwards 29M USD +15.5%
Preferred Stock, Shares Authorized 5M shares
Lessee, Operating Lease, Liability, to be Paid, Year Four 133K USD -33.5%
Additional Paid in Capital 425M USD +1.54%
Amortization of Intangible Assets 49K USD +36.1%
Interest Expense 585K USD
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares